DOI QR코드

DOI QR Code

A Case of Statin-Induced Interstitial Pneumonitis due to Rosuvastatin

  • Kim, Se Yong (Department of Internal Medicine, The Armed Forces Medical Hospital) ;
  • Kim, Se Jin (Department of Internal Medicine, The Armed Forces Medical Hospital) ;
  • Yoon, Doran (Department of Internal Medicine, Seoul National University Hospital) ;
  • Hong, Seung Wook (Department of Internal Medicine, Seoul National University Hospital) ;
  • Park, Sehhoon (Department of Internal Medicine, Seoul National University Hospital) ;
  • Ock, Chan-Young (Department of Internal Medicine, Seoul National University Hospital)
  • 투고 : 2015.01.28
  • 심사 : 2015.03.26
  • 발행 : 2015.04.30

초록

Statins lower the hyperlipidemia and reduce the incidence of cardiovascular events and related mortality. A 60-year-old man who was diagnosed with a transient ischemic attack was started on acetyl-L-carnitine, cilostazol, and rosuvastatin. After rosuvastatin treatment for 4 weeks, the patient presented with sudden onset fever, cough, and dyspnea. His symptoms were aggravated despite empirical antibiotic treatment. All infectious pathogens were excluded based on results of culture and polymerase chain reaction of the bronchoscopic wash specimens. Chest radiography showed diffuse ground-glass opacities in both lungs, along with several subpleural ground-glass opacity nodules; and a foamy alveolar macrophage appearance was confirmed on bronchoalveolar lavage. We suspected rosuvastatin-induced lung injury, discontinued rosuvastatin and initiated prednisolone 1 mg/kg tapered over 2weeks. After initiating steroid therapy, his symptoms and radiologic findings significantly improved. We suggest that clinicians should be aware of the potential for rosuvastatin-induced lung injury.

키워드

참고문헌

  1. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-50. https://doi.org/10.1001/jama.279.20.1643
  2. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23 Suppl 1):III50-7. https://doi.org/10.1161/01.CIR.0000116208.41269.75
  3. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005;111:3051-7. https://doi.org/10.1161/CIRCULATIONAHA.105.555482
  4. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995;25:745-6. https://doi.org/10.1111/j.1445-5994.1995.tb02870.x
  5. Liebhaber MI, Wright RS, Gelberg HJ, Dyer Z, Kupperman JL. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999;115:886-9. https://doi.org/10.1378/chest.115.3.886
  6. Veyrac G, Cellerin L, Jolliet P. A case of interstitial lung disease with atorvastatin (Tahor) and a review of the literature about these effects observed under statins. Therapie 2006;61:57-67. https://doi.org/10.2515/therapie:2006017
  7. Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest 2008;134:824-30. https://doi.org/10.1378/chest.08-0943
  8. Huang LK, Tsai MJ, Tsai HC, Chao HS, Lin FC, Chang SC. Statin-induced lung injury: diagnostic clue and outcome. Postgrad Med J 2013;89:14-9. https://doi.org/10.1136/postgradmedj-2011-130209
  9. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012;13:39. https://doi.org/10.1186/1465-9921-13-39

피인용 문헌

  1. Rosuvastatin : Drug-induced interstitial lung disease: case report vol.1601, pp.1, 2016, https://doi.org/10.1007/s40278-016-17511-6